Ignacio Garrido-Laguna, MD, PhD, MBA

Ignacio Garrido-Laguna, MD, PhD, MBA, is a professor of oncology, director of the Phase 1 Program, and co-leader of the GI Oncology Multidisciplinary Disease Group at the University of Utah School of Medicine.

Articles by Ignacio Garrido-Laguna, MD, PhD, MBA

Dr Garrido-Laguna on the Safety of Daraxonrasib in KRAS G12X–Mutated PDAC

ByIgnacio Garrido-Laguna, MD, PhD, MBA

March 11th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses the safety profile of daraxonrasib in patients with KRAS-mutated pancreatic ductal adenocarcinoma

Dr Garrido-Laguna on the Safety and Efficacy of Daraxonrasib in KRAS-Mutated PDAC

ByIgnacio Garrido-Laguna, MD, PhD, MBA

February 6th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.

Dr Garrido-Laguna on the Mechanism of Action of RMC-6236 in KRAS-Mutant PDAC

ByIgnacio Garrido-Laguna, MD, PhD, MBA

October 27th 2023

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.

JAK Inhibitors Used as Anti-inflammatory Therapeutics for Pancreatic Cancer

ByIgnacio Garrido-Laguna, MD, PhD, MBA

August 23rd 2015

Experts review ongoing clinical research with JAK inhibitors in advanced pancreatic cancer as well as some strategies for preclinical testing of vertical inhibition of the JAK pathway.